A
A
Home

Clinical Trials

At argenx, we are united in our commitment to improve the lives of patients by translating immunology innovations into transformative medicines.

The path to pioneer innovations and advance the understanding of autoimmune disease is best achieved through co-creation with patients and their supporters, and our patient advocacy partners.

Most important to our mission are the people who choose to participate in our clinical trials.

 

Efgartigimod

Generalized Myasthenia Gravis (gMG)

ADAPT NXT

Phase 3 trial of IV efgartigimod for the treatment of generalized MG. Completed.
Program: Efgartigimod

Primary Immune Thrombocytopenia (ITP)

ADVANCE

Phase 3 trial of IV efgartigimod for the treatment of primary ITP
Program: Efgartigimod

ADVANCE SC

Phase 3 trial evaluating SC efgartigimod for the treatment of primary ITP
Program: Efgartigimod

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

ADHERE

Phase 2 trial of SC Efgartigimod for the treatment of CIDP
Program: Efgartigimod

Pemphigus Vulgaris (PV)

Bullous Pemphigoid (BP)

Idiopathic Inflammatory Myopathies (Myositis)

Post-COVID Postural Orthostatic Tachycardia Syndrome (PC-POTS)

Primary Sjogren’s Syndrome (pSS)

RHO STUDY

Phase 2 trial of IV efgartigimod for the treatment of primary Primary Sjögren’s Syndrome
Program: Efgartigimod

ARGX-117

Multifocal Motor Neuropathy (MMN)

ARGX-117

A Phase 2, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Group, Multicenter Trial to Evaluate the Safety and Tolerability, Efficacy, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of 2 Dose Regimens of ARGX-117 in Adults With Multifocal Motor Neuropathy
Program: ARGX-117

More information
argenx MMN study website

iMMersioN

A Multicenter Prospective Longitudinal Study of Clinical Outcomes, Disease Course, Health-Related Quality of Life, and Health Care Resource Utilization in Adult Patients With Multifocal Motor Neuropathy.

More information

Post-Trial Access

At argenx, we believe participation in a clinical trial within a controlled setting is the most appropriate way to access investigational products.

argenx recognizes that during a clinical trial, some participants may feel they have benefited from the investigational product, yet they do not have access to the product after their participation in the trial has ended because it is not yet approved or commercially available in their country.

When an individual request is received from a clinical trial investigator to continue to provide an investigational product to a patient outside the trial, that is commonly referred to as post-trial access.